Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical… Read more
Endonovo Therapeutics Inc (ENDV) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.001x
Based on the latest financial reports, Endonovo Therapeutics Inc (ENDV) has a cash flow conversion efficiency ratio of 0.001x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.84K) by net assets ($-27.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Endonovo Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Endonovo Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Endonovo Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Endonovo Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Seven Principles AG
XETRA:T3T1
|
-0.092x |
|
Blue Ribbon Income Fund
TO:RBN-UN
|
0.013x |
|
Biomotion Sciences Warrant
NASDAQ:SLXNW
|
-0.407x |
|
Mango Capital Inc
PINK:MCAP
|
0.263x |
|
LOGN3F
SA:LOGN3F
|
N/A |
|
Neon Equity AG
XETRA:D77
|
N/A |
|
CANTOURAGE GROUP SE O.N.
F:HIGH
|
N/A |
|
Picton Property Income Ltd
LSE:PCTN
|
0.018x |
Annual Cash Flow Conversion Efficiency for Endonovo Therapeutics Inc (2010–2024)
The table below shows the annual cash flow conversion efficiency of Endonovo Therapeutics Inc from 2010 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-26.80 Million | $100.49K | -0.004x | +25.84% |
| 2023-12-31 | $-24.11 Million | $121.87K | -0.005x | -123.97% |
| 2022-12-31 | $-32.18 Million | $-678.84K | 0.021x | -66.27% |
| 2021-12-31 | $-15.77 Million | $-986.58K | 0.063x | +21.22% |
| 2020-12-31 | $-14.37 Million | $-741.59K | 0.052x | -58.37% |
| 2019-12-31 | $-20.50 Million | $-2.54 Million | 0.124x | -50.96% |
| 2018-12-31 | $-11.39 Million | $-2.88 Million | 0.253x | -19.28% |
| 2017-12-31 | $-9.55 Million | $-2.99 Million | 0.313x | +8.85% |
| 2016-12-31 | $-8.56 Million | $-2.46 Million | 0.288x | +114.13% |
| 2015-12-31 | $-7.59 Million | $-1.02 Million | 0.134x | -30.68% |
| 2014-12-31 | $-4.69 Million | $-909.30K | 0.194x | +211.03% |
| 2013-12-31 | $-4.13 Million | $-257.42K | 0.062x | -58.87% |
| 2012-12-31 | $-1.88 Million | $-284.89K | 0.151x | +121.64% |
| 2011-12-31 | $71.96K | $-50.35K | -0.700x | -1466.62% |
| 2010-12-31 | $166.05K | $8.50K | 0.051x | -- |